Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Characterisation of DEHAL1 expression in thyroid pathologies.

Kerstin Krause1, Stefan Karger, Oliver Gimm

  • 1III. Medical Department, University of Leipzig, Ph.-Rosenthal-Str. 27, 04103 Leipzig, Germany.

European Journal of Endocrinology
|February 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement mediated thrombotic microangiopathy after liver transplantation in combination with a novel C6 variant of uncertain significance.

Frontiers in immunology·2026
Same author

Thyroid hormone therapy in a population cohort over two decades indicates persistent overtreatment.

European thyroid journal·2026
Same author

PSMB8 stratifies therapy response in eosinophilic esophagitis.

Clinical and experimental immunology·2026
Same author

CHD4 and NOX4 expression in thyroid tumor tissues.

Exploration of targeted anti-tumor therapy·2026
Same author

Corrigendum to: "A rare vascular puzzle: Portal hypertension and hepatic lesions" [J Hepatol (2026) 84: e59-61].

Journal of hepatology·2026
Same author

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer.

BMC cancer·2026
Same journal

Long-term Cancer Risk in Acromegaly: A Population-Based Cohort Study with 44 Years of Follow-up.

European journal of endocrinology·2026
Same journal

Psychosocial retrospective follow-up of young adults with congenital adrenal hyperplasia.

European journal of endocrinology·2026
Same journal

Correction to: Steroidogenic factor-1 regulates a core set of target genes to promote malignancy in adrenocortical carcinoma.

European journal of endocrinology·2026
Same journal

Improving post-thyroidectomy care using a PTH and calcium-based algorithm.

European journal of endocrinology·2026
Same journal

Sampling variability and concordance between sequential and simultaneous adrenal venous sampling in primary aldosteronism subtype diagnosis.

European journal of endocrinology·2026
Same journal

Independent Clonal Evolution in Primary Pigmented Nodular Adrenocortical Disease: A Single-Patient Multi-Omics Study.

European journal of endocrinology·2026
See all related articles

Iodotyrosine dehalogenase 1 (DEHAL1) is upregulated in toxic thyroid conditions but downregulated in advanced thyroid cancers. DEHAL1 expression levels and localization may indicate thyroid cell differentiation status.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Iodotyrosine dehalogenase 1 (DEHAL1) is a key transmembrane protein in iodide recycling within the human thyroid gland.
  • Understanding DEHAL1's role is crucial for diagnosing and managing various thyroid pathologies.

Purpose of the Study:

  • To investigate differential DEHAL1 expression across various thyroid pathologies.
  • To evaluate DEHAL1 as a potential biomarker for thyroid cell differentiation.

Main Methods:

  • Real-time PCR was used to quantify DEHAL1 and DEHAL1B mRNA in 105 thyroid specimens.
  • Immunohistochemistry assessed DEHAL1 protein expression in 163 thyroid samples.
  • Specimens included normal thyroids, toxic nodules, Graves' disease, cold nodules, and various thyroid cancers.

Related Experiment Videos

Main Results:

  • Highest DEHAL1 mRNA levels were observed in Graves' disease thyroids.
  • Downregulation of DEHAL1 mRNA was noted in papillary and anaplastic thyroid carcinomas.
  • DEHAL1 protein was overexpressed in toxic nodules and Graves' disease, with apical staining; differentiated cancers showed diffuse cytoplasmic staining, while poorly differentiated cancers had faint or absent expression.

Conclusions:

  • Upregulated DEHAL1 protein and apical localization in toxic conditions correlate with increased thyroid hormone turnover.
  • Altered or reduced DEHAL1 expression in thyroid cancers suggests a loss of function during dedifferentiation.
  • DEHAL1 expression patterns may serve as an indicator of thyroid cell differentiation and malignancy.